Affimed Therapeutics B.V. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology. The Company's TandAbs has the ability to bring NK-cells or T-cells into proximity and trigger a signal cascade that leads to the destruction of cancer cells. Its product pipeline includes AFM13, AFM11 and AFM21. Affimed Therapeutics B.V. is headquartered in Heidelberg, Germany.
technical indicators:
- Trend Spotter buy signal
- Above its 20, 50 and 100 day moving averages
- 7 new highs and up 19.36% in the last month
- Relative Strength Index 74.21%
- Barchart computes a technical support level at 13.68
- Recently traded at 14.49 with a 50 day moving average of 10.54
Fundamental factors:
- Market Cap $347.47 million
- Revenue expected to grow 92.10% this year and another 77.40% next year
- Earnings estimates for the next 5 years have not been projected
- Wall Street analysts issued 3 strong buy and 1 buy recommendation on the stock
The 20-100 Day MACD Oscillator has been an effective technical trading strategy for this stock.
No comments:
Post a Comment